The Centers for Medicare & Medicaid Services (CMS) has selected 15 drugs for Medicare price negotiations, including the popular type 2 diabetes drug dulaglutide (Trulicity) and botulinum toxin (Botox).[1] These drugs also include preparations for the treatment of psoriatic arthritis, prostate cancer and breast cancer. The program allows Medicare to directly negotiate prices for high-cost drugs without generic or biosimilar competition.[2] The top 10 drugs have negotiated prices effective from 2026, with expected savings of $1.5 billion in out-of-pocket costs for patients and $6 billion for the Medicare program annually.[1][2] The prices of these 10 drugs will drop by at least 38% compared to the 2023 price.[1] Another 15 drugs, including blockbusters like Ozempic, will be negotiated for 2027.[1] All eligible Medicare beneficiaries will have access to these lower prices.[1]